Charles River collaborates with Akron Bio to enhance integration of CGMP materials into cell therapy platform

WASHINGTON (dpa-AFX) – Charles River Laboratories International, Inc. (CRL) and Akron Bio announced Thursday the integration of Akron’s Closed System Solutions (CSS) line of liquid cytokines manufactured in accordance with current good manufacturing practices (CGMP) into Charles River Cell Therapy. A flexible platform for process development.

The integration of Akron’s liquid cytokine line further enables a closed processing system that streamlines operations, minimizes risk and improves process reliability.

Charles River’s Cell Therapy Flex platform was designed as an off-the-shelf solution for cell therapy process development, offering ready-to-use platforms and protocols validated for autologous CAR-T and TCR-T cell therapy to minimize risk, reduce costs, and speed development .

Charles River’s Cell Therapy Flex platform includes Akron’s CGMP liquid cytokines, including rHu IL-2, IL-7, IL-15 and IL-21, now available in proprietary liquid formulations that maintain the stability of these proteins at 2-8° C.

These materials are ready-to-use, available in single-use bags with sealed tubing, minimizing the risk of operator error while ensuring rapid, seamless preparation of aseptic environments.